Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MICAFUNGIN SODIUM

All injection strengths: not a benefit

Other products in the same Health Canada class (J02A, J02AX) — coverage varies; not interchangeable

  • Caspofungin (Cancidas): not a benefit
  • Amphotericin b (Fungizone): general benefit
  • Fluconazole (Diflucan P.O.S.): general benefit, Limited Use 528, Not a benefit
  • Itraconazole (Sporanox): general benefit, Limited Use 570, Not a benefit
  • Ketoconazole (Nizoral): general benefit, Not a benefit
  • Voriconazole (Vfend): limited Use 399

1 more in the class list below

Mycamine · DIN 02311054 · 100mg/Vial · injection Pd-10mL vial

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.Discontinued 2026-07-31 · checked 2026-09-19
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mycamine · DIN 02311054 Manufacturer: Sandoz Canada Inc.; listing date 2023-09-28 Health Canada: Cancelled post market since 2026-07-31 · brand MYCAMINE · ATC J02AX05 MICAFUNGIN · form Powder for solution · route Intravenous · ingredients MICAFUNGIN SODIUM 100 MG/VIAL · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Mycamine: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79665 · Verify on the e-Formulary ↗ (DIN 02311054)

Source record
The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02311054). DIN 02311054: Mycamine Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 081204036; group id 13; item number 0017; lccId None; manufacturer id SDZ Source form: Inj Pd-10mL Vial Pk; strength: 100mg/Vial Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02311054 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=79665
Interchangeable products
Micafungin Sodium for Injection · DIN 02524961 · $186.2000 Micafungin Sodium for Injection · DIN 02547236 · $186.2000
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2026-07-31 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:12:04 Antifungals) and how they are covered

Matched class: 08:12:04 Antifungals

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMPHOTERICIN B Some products covered without a code (check the product listing): FLUCONAZOLE, ITRACONAZOLE, KETOCONAZOLE, NYSTATIN, TERBINAFINE HCL 08:12:04 Antifungals

CASPOFUNGIN ACETATE

· 3 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg/Vial · Inj-Vial Pk

AMPHOTERICIN B

· 1 products · General benefit · strengths: · Inj Pd-50mg Pk

FLUCONAZOLE

· 17 products · Limited Use, codes 528 (1), Listed, not a benefit (2), General benefit (14) · strengths: 10mg/mL, 50mg, 100mg · O/L, Tab

ITRACONAZOLE

· 5 products · General benefit (2), Listed, not a benefit (1), Limited Use, codes 570 (2) · strengths: 100mg, 10mg/mL · Cap, Oral Sol

KETOCONAZOLE

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 200mg · Tab

VORICONAZOLE

· 6 products · Limited Use, codes 399 · strengths: 50mg, 200mg · Tab

POSACONAZOLE

· 7 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 100mg, 40mg/mL · DR Tab, O/L

NYSTATIN

· 3 products · Listed, not a benefit (1), General benefit (2) · strengths: 100000U/mL · O/L

TERBINAFINE HCL

· 8 products · Listed, not a benefit (1), General benefit (7) · strengths: 250mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:12:04
Full class listing Related classes: 08:12:07 Carbapenems, 08:12:12 Erythromycins, 08:12:16 Penicillins, 08:12:24 Tetracyclines, 08:12:28 Other Antibiotics, 08:14:08 Azoles Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Micafungin Sodium for Injection (micafungin sodium) is indicated for use in adults and children 4 months and older for:  Treatment of patients with Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses infections. Micafungin sodium for injection has not been adequately studied in patients with endocarditis, osteomyelitis and meningitis due to Candida infections.  Treatment of patients with esophageal candidiasis.  Prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation. Geriatrics (> 65 years of age): No overall differences in safety or effectiveness have been observed between geriatric subjects (> 65 years) and younger subjects in clinical studies. Pediatrics (4 months - 16 years): The safety and effectiveness of Micafungin Sodium for Injection in pediatric patients aged four (4) months to 16 years of age have been supported by evidence from adequate and well- controlled studies in adult and pediatric patients as well as pharmacokinetic data in pediatric patients. The safety and efficacy of Micafungin Sodium for Injection in pedi… https://pdf.hres.ca/dpd_pm/00064616.PDF PM date: not printed or not captured Source product: MICAFUNGIN SODIUM FOR INJECTION; DIN 02524953; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Mycamine: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026